Literature DB >> 1355411

Report of the Conference on Low Blood Cholesterol: Mortality Associations.

D Jacobs, H Blackburn, M Higgins, D Reed, H Iso, G McMillan, J Neaton, J Nelson, J Potter, B Rifkind.   

Abstract

BACKGROUND: A National Heart, Lung, and Blood Institute (NHLBI) Conference was held October 9-10, 1990, to review and discuss existing data on U-shaped relations found between mortality rates and blood total cholesterol levels (TC) in some but not other studies. Presentations were given from 19 cohort studies from the United States, Europe, Israel, and Japan. A representative of each study presented its findings and also submitted tables of proportional hazards regression coefficients for entry TC levels in regard to death, and these were incorporated into a formal statistical overview adjusted for age, diastolic blood pressure, cigarette smoking, body mass index, and alcohol intake, as available. METHODS AND
RESULTS: The U-shape for total mortality in men and the flat relation in women resulted largely from a positive relation of TC with coronary heart disease death and an inverse relation with deaths caused by some cancers (e.g., lung but not colon), respiratory disease, digestive disease, trauma, and residual deaths. Risk for combined noncardiovascular, noncancer causes of death decreased steadily across the range of TC. The conference considered possible explanations for the statistical associations found between low TC levels or active TC lowering and certain causes of death. One is that TC is lowered by some disease conditions themselves, such as wasting in chronic pulmonary disease or reduced production and secretion of cholesterol-bearing lipoproteins with liver disease. In this sort of situation, the TC:mortality association found in observational studies may be due to preexisting disease. This was addressed by excluding early deaths from the analysis, which did not change the results. The conference considered as well the biological function of cholesterol, which, if seriously deranged, might hypothetically cause a wide variety of diseases and dysfunction. The conference also considered the biological functions that might provide plausible mechanisms for the associations found.
CONCLUSIONS: Definitive interpretation of the associations observed was not possible, although most participants considered it likely that many of the statistical associations of low or lowered TC level are explainable by confounding in one form or another. The conference focused on the apparent existence and nature of these associations and on the need to understand their source rather than on any pertinence of the findings for public health policy. Further research is recommended to explain the observed associations of low TC levels (and TC lowering) with certain noncardiovascular diseases. This includes studies of the time course of TC change in disease, the relation of TC to morbidity, further studies of possible epidemiological confounding, monitoring of population trends in TC and mortality, further studies of the relations in women, auditing of noncardiovascular events in trials, studies of cell membrane, genetic and molecular links to cholesterol metabolism, TC level and disease, studies of disease manifestations in specific lipid disorders, and further study of the proposed causal mechanisms linking low TC and hemorrhagic stroke.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355411     DOI: 10.1161/01.cir.86.3.1046

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  137 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Serum total cholesterol in nosocomial infections after gastrointestinal surgery.

Authors:  Mitsuaki Morimoto; Yosikazu Nakamura; Sadakane Atsuko; Takashi Nagaie; Ken Shirabe
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 3.  Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry.

Authors:  Beatrice Alexandra Golomb; Michael H Criqui; Halbert White; Joel E Dimsdale
Journal:  Arch Intern Med       Date:  2004-01-26

Review 4.  Early use of statins in acute coronary syndromes.

Authors:  Joshua M Spin; Randall H Vagelos
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 5.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

6.  Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.

Authors:  S Warshafsky; D Packard; S J Marks; N Sachdeva; D M Terashita; G Kaufman; K Sang; A J Deluca; S J Peterson; W H Frishman
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

7.  Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study.

Authors:  Seamus P Whelton; Probal Roy; Brad C Astor; Lin Zhang; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh
Journal:  Am J Epidemiol       Date:  2013-09-10       Impact factor: 4.897

8.  Low serum total cholesterol concentrations and mortality in middle aged British men.

Authors:  G Wannamethee; A G Shaper; P H Whincup; M Walker
Journal:  BMJ       Date:  1995-08-12

9.  Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer.

Authors:  Z Chen; A Keech; R Collins; B Slavin; J Chen; T C Campbell; R Peto
Journal:  BMJ       Date:  1993-04-03

Review 10.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.